Novartis in Pivotal Point Check: Focus on Patented Medications Pays Off – Dividend Increase to CHF 3.50 After Strong Q4!
Reading Time: 2 minutes
In the fiscal year 2024, revenue increased by 11% to $50.3 billion. The strategy of focusing on innovative, patented drugs is working. The blockbuster Entresto increased its revenue by 30% to a remarkable $7.8 billion. The pharmaceutical company grew significantly in the fourth quarter of 2024. Between October and December, Novartis generated $13.2 billion (approximately €12.7 billion), achieving a 15% increase compared to the same period last year. Operational earnings for Novartis in the fourth quarter amounted to $3.5 billion, representing...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
